Hypromellose

Summary

Hypromellose (CHEMBL2108956) is an approved unknown (ATC S01KA02); indicated across 5 conditions including dry eye syndrome and ophthalmic herpes zoster.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: S01KA02
• Indications: 5 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108956
Name	Hypromellose
Type	Unknown
Max phase	4
ATC	S01KA02

Also known as: Artelac, Artelac sdu, Brolene, Dacriosol, Gonisol, Hipromelosa, Hydroxypropyl methylcelluloses, Hydroxypropylmethylcellulose, Hypromellose, Hypromellose 4000, unspecified, Hypromelloses

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
dry eye syndrome	3	MONDO:0006733	EFO:1000906
ophthalmic herpes zoster	2	MONDO:0005883	EFO:0007403
polyp	2	MONDO:0005079	EFO:0000662
Acanthamoeba keratitis	2	MONDO:0005629	EFO:0007126
hepatitis C virus infection	1	MONDO:0005231	EFO:0003047

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE4	8
Not specified	4
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00598689	PHASE4	COMPLETED	GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients
NCT01280110	PHASE4	COMPLETED	The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients
NCT01387620	PHASE4	COMPLETED	Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2%
NCT01881126	PHASE4	COMPLETED	An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
NCT01978015	PHASE4	COMPLETED	Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG
NCT02097719	PHASE4	COMPLETED	Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
NCT05265910	PHASE4	COMPLETED	A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
NCT05314621	PHASE4	COMPLETED	A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis
NCT03697876	PHASE1	COMPLETED	Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
NCT01284439	Not specified	UNKNOWN	Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma
NCT01791426	Not specified	WITHDRAWN	A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye
NCT02420834	Not specified	COMPLETED	Dry Eye Treatment With Artificial Tears
NCT04868175	Not specified	COMPLETED	Interval Intraocular Pressure in Intravitreal Injection Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).